linjc16/ctgov huggingface dataset:
Back to the Traditional: Anti-COX Drugs Can Improve the Outcome of COVID-19 Patients Admitted to ICU

Study Overview
=================
Brief Summary
-----------------
Retrospective multicenter study to evaluate the data of COVID-19 patients who were admitted to university hospitals in relation to their recent administration or maintenance on non-steroidal anti-inflammatory drugs (NSAID) prior to have COVID-19 disease and to analyze it in relation to outcome of these patients.

Detailed Description
-----------------
The data contained in hospital registry were collected, categorized into demographic, previous medical history, the use of NSAID as maintenance therapy or its recent administration before diagnosis of COVID-19 disease, presenting manifestations, laboratory and CT findings, applied therapies or interventions. Outcomes will be categorized as survival and non-survival outcome. Survivors will be subdivided as complete recovery or recovery with getting new morbidities. Mortality was subdivided as total hospital and ICU mortality. Data will be statistically analyzed in relation to outcomes

Official Title
-----------------
Back to the Traditional: Anti-COX Drugs Can Improve the Outcome of COVID-19 Patients Admitted to ICU

Conditions
-----------------
COVID-19 Disease

Intervention / Treatment
-----------------
* Other: File inquiry


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: assured diagnosis of COVID-19 by RT-PCR Exclusion Criteria: No
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No NSAID<br>included patients who did not receive NSAID prior to having COVID-19 disease | Other: File inquiry<br>* Data extraction out of file registry<br>* Other names: No interventions;|
| Apsirin<br>included patients who received acetylsalicylic acid (ASA) prior to having COVID-19 disease | Other: File inquiry<br>* Data extraction out of file registry<br>* Other names: No interventions;|
| Celecoxib<br>included patients who received celecoxib (CEL) prior to having COVID-19 disease | Other: File inquiry<br>* Data extraction out of file registry<br>* Other names: No interventions;|
| Miscellaneous<br>included patients who received miscellaneous NSAID other than ASA or CEL prior to having COVID-19 disease | Other: File inquiry<br>* Data extraction out of file registry<br>* Other names: No interventions;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality rate | number of patients who were died secondary to COVID-19 disease or its complications | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID-19, NSAID, Aspirin, Mortality
Rajavtihi Neuronal Adult Stem Cells Project

Study Overview
=================
Brief Summary
-----------------
To study the success of Oligodendrocyte progenitor cell culture project in Rajavithi Hospital to identify an unlimited clone human neuronal progenitor stem cells from the human brain in the Biomolecular Research Center. This study aims to produce the reproductive clone of neuronal development protocols and advance projects. Neuronal cells such as pyramidal cells, oligodendrocyte, and dopaminergic neuron differentiation protocol/projects for treatment of Alzheimer's disease, Multiple sclerosis, and Parkinson's disease respectively in next phase of clinical trials.

Official Title
-----------------
Adult Neuronal Progenitor Stem Cell Project

Conditions
-----------------
Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis

Intervention / Treatment
-----------------
* Other: Progenitor Stem Cell Culture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who have elective craniotomy or. Patients who have elective ventriculostomy surgery or. Patients who have elective muscle biopsy or nerve biopsy. Patient who have emergency craniectomy for life threatening from emergency medical and surgical conditions such as Brain herniation or head injury Exclusion Criteria: Central nervous system infection for example tuberculous or any bacterial infection, Viral infection, fungal infection. Central nervous system Tumor, Malignancy and metastasis.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 120 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Interventional Model Description: Cell culture
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Progenitor Stem Cell Culture|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Adult Progenitor Stem cells, Alzheimer's disease, Parkinson's disease, Multiple sclerosis
Sequence and Time-of-day Infusion of immunoCHemotherapy Affect Response in Oesophageal Cancer in the NeOadjuvant Setting

Study Overview
=================
Brief Summary
-----------------
It is reported that compared to chemotherapy alone, immunochemotherapy has significantly improved the overall survival of patients with advanced metastatic ESCC. However, there are still more than 30% of patients who cannot benefit from this treatment modality. In addition to these factors, the time-of-day infusion and administration sequence of immunochemotherapy have been reported to be associated with tumor responses and overall survival. In this study, The investigators aimed to explore the roles of infusion time and administration sequence of immunochemotherapy in predicting tumor responses and overall survival in patients with advanced ESCC.

Official Title
-----------------
Effect of Immunochemotherapy Sequence and Time-of-day Infusion on Efficacy and Prognosis of Patients With Advanced Esophageal Squamous Cell Carcinoma

Conditions
-----------------
Esophagus Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pathologically diagnosed as esophageal squamous cell carcinoma KPS≥80 Adequate organ function No distant metastasis The diseases could be resected or potentially resectable after immunochemotherapy assessed by a thoracic oncologist Exclusion Criteria: incomplete medical record which affects statistical analysis have participated in previous interventional clinical trials other situations evaluated by investigators not meet the enrollment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 78 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival | Overall survival rate | from the date of diagnosis to the date of death, assessed up to 100 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pathologic complete response rate (pCR) | The rate of pathologic complete response rate after the combined treatment of chemotherapy and immunotherapy following surgery | Three to five working days after surgery |
Relationship Between Muscle Strength and Physical Function in ICU

Study Overview
=================
Brief Summary
-----------------
This observational study aims to assess the relationship between muscle strength and physical function in critical ill patients. Grip and quadriceps strengths are measured using a standardized protocol of dynamometry. Physical function is assessed using the validated ICU mobility scale.

Official Title
-----------------
Analysis of the Relationship Between Muscle Strength and Physical Function in ICU Survivors

Conditions
-----------------
Critical Illness, Muscle Weakness, Physical Disability, Physical Dependence

Intervention / Treatment
-----------------
* Diagnostic Test: Quadriceps strength
* Diagnostic Test: Grip strength
* Diagnostic Test: ICU mobility scale


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ICU stay of at least 48h Collaborative (RASS score -1 to +1) Exclusion Criteria: Refusal Coma Non collaborative Hemi / tetra paresis or plegia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Quadriceps strength|Using a handheld dynamometer, in supine position in a standardized position of the dominant leg Measurement of the maximal isometric voluntary quadriceps contraction Measure expressed as Newton and Newton/kg|
|Diagnostic Test: Grip strength|Testing of dominant hand using a handgrip Measurement of the maximal isometric voluntary grip contraction Measure is expressed as kg|
|Diagnostic Test: ICU mobility scale|Scoring the physical capacity of the patient on a 10-points validated scale: the ICU mobility scale|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quadriceps strength | Quadriceps maximal isometric strength measured using dynamometry | as soon as collaborative during ICU stay and up to 1 month following ICU discharge | 
| Handgrip strength | Grip maximal isometric strength measured using dynamometry | as soon as collaborative during ICU stay and up to 1 month following ICU discharge | 
| ICU mobility scale | Ranking the patient on the scale according to his/her physical capacity. ICU mobility scale is a 10 points scale: 0 means the patient is lying in bed, 10 means the patient is able to walk independently | as soon as collaborative during ICU stay and up to 1 month following ICU discharge |
Composite Graft Use in Abdominal Sacrocolpopexy Reduces Erosion Rates

Study Overview
=================
Brief Summary
-----------------
This study is to determine whether the use of a composite biologic/synthetic graft during abdominal sacrocolpopexy leads to a lower rate of erosion while maintaining durability.

Detailed Description
-----------------
This study will examine the erosion rate of a composite graft that is being used during abdominal sacrocolpopexy. The composite graft is composed of a dual layer of biological and syntheric material. Biological grafts have the advantage of significantly reducing erosion rates, but the longevity of biologic graft is uncertain. On the other hand, synthetic grafts have the advantage in that they are durable, but have higher erosion rates through the vagina and require re-operation in a small percentage of patients. This study will look at whether or not the use of a composite greaft carries the advantages of both types of materials and leads to decreased rates of erosion while maintaining longevity. The cost effectiveness of this new type of graft will also be reviewed since the disavantage of utilizing both the synthetic and biologic graft is that it will increase the cost.

Official Title
-----------------
Composite Graft Use in Abdominal Sacrocolpopexy Reduces Erosion Rates

Conditions
-----------------
Pelvic Organ Prolapse

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who underwent abdominal sacrocolpopexy with Drs. Noblett and Lane from 2001 to present Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The erosion rates of composite biologic/syntheric grafts and synthetic-only grafts will be compared. |  | To the point of graft erosion after abdominal sacrocolpopexy | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cost effectiveness will be examined by comparing the price of a composite graft to the cost of re-operation due to erosion of a synthetic-only graft. |  | To the point of graft erosion after abdominal sacrocolpopexy | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pelvic organ prolapse, Composite biologic/synthetic graft, Abdominal sacrocolpopexy
Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement

Study Overview
=================
Brief Summary
-----------------
The primary objectives were to determine the efficacy and safety of the GITS formulation of Doxazosin in Taiwanese patients with prostate enlargement.

Official Title
-----------------
A Prospective, Open-Labeled Trial of the Safety and Efficacy of Doxazosin GITS in Patients With Benign Prostate Hyperplasia

Conditions
-----------------
Prostate

Intervention / Treatment
-----------------
* Drug: Doxazosin mysylate GITS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Taiwanese male subjects between 50 and 80 years of age who had: a primary diagnosis of BPH, defined as having an enlarged prostate (confirmed by digital rectal examination [DRE] and/or B-mode ultrasound); an IPSS score of ≥12; and a Qmax in the range of 5 to 15 mL/sec in a total voided volume of ≥150 mL, were eligible for the study. Exclusion criteria include but not limited to: Previous prostate surgery, presence of a prostate stent or microwave thermotherapy and/or balloon dilatation within the previous 6 months Concomitant therapy or previous therapy within 14 days with agents known to affect bladder or urethral function.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: A<br> | Drug: Doxazosin mysylate GITS<br>* Subjects initiated on 4 mg doxazosin GITS once daily at Visit 1 for four weeks. At Visit 2 (Week 4) increased to 8 mg Doxazosin GITS if efficacy response criteria not met.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in the maximum urinary flow rate (Qmax) from baseline |  | 8 weeks | 
| Change in the International Prostate Symptom Score (IPSS) total score from baseline |  | 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in the International Prostate Symptom Score (IPSS) total score from baseline |  | 4 weeks | 
| Change in the maximum urinary flow rate (Qmax) from baseline |  | 4 weeks | 
| Change in the quality of life (QoL) assessment index score from baseline |  | 8 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Benign Prostate Hyperplasia
Comparative Study of Osteosynthesis for Chevron Osteotomy of Hallux Valgus Using Degradable Versus Non-degradable Metallic Device

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to show the equivalence of a new degradable metallic device to a non-degradable metallic device in patients with Hallux Valgus.

Conditions
-----------------
Hallux Valgus

Intervention / Treatment
-----------------
* Device: Fracture compressing screw ZfW 102 Königsee Implantate GmbH
* Device: Fracture compressing screw titanium Königsee Implantate GmbH


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female and male patients with an age of 40 to 79 years at the day of surgery Symptomatic Hallux Valgus Radiological criterium area of proximal joint angle Normal motorically functions Female patients of childbearing age must be using two reliable contraception methods Exclusion Criteria: Previous bone and/or soft tissue surgeries of the the first metatarsal of the respective foot BMI > 32 Cysts of the first metatarsal of the respective foot Neurological disorders with modified motorically functions Clinical evidence of osteoporosis Chronic renal impairment Known hypersensitivity to components of the implants Regular administration of medications containing the metallic elements of the degradable implant Pregnant or lactating women Current participation in another clinical trial or within 30 days before surgery

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 79 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: degradable metallic device<br> | Device: Fracture compressing screw ZfW 102 Königsee Implantate GmbH<br>* Comparison of two metallic implantable fracture compressing screws<br>|
| Active Comparator: non-degradable metallic device<br> | Device: Fracture compressing screw titanium Königsee Implantate GmbH<br>* Comparison of two metallic implantable fracture compressing screws<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| difference of metatarsal angles in degree post surgery and 6 months after surgery |  | up to 6 months |
The Efficacy, Safety and Genetic Polymorphism of Hypoca and Adalat OROS in Hypertensive Patients

Study Overview
=================
Brief Summary
-----------------
Nifedipine and barnidipine act as calcium channel blockers, and are widely prescribed for pressure control of prehypertension and stage 1 hypertension. CYP3A4 is responsible for the metabolism of nifedipine and nifedipine, while the contribution of CYP3A5 remains ambiguous. This study is aimed to analyze the association between antihypertensive effects of nifedipine as well as barnidipine and single nucleotide polymorphisms of CYP3A4, CYP3A5 and calcium channels.

Detailed Description
-----------------
For each drug, 20 patients will be enrolled. Patients' blood pressure and heart rates will be measured at first visit, followed by visits at week4 , week 8 and week 12. Blood samples will be drawn at week 4 and week 12 for following analyses of drug plasma concentrations. SNPs in CYP3A4, CYP3A5 and calcium channel v 1.2 will be genotyped using SNPstream. The differences in the decrease of blood pressures and the durg plasma concentrations between genotypes will be analyzed.

Official Title
-----------------
An Open-Label, Randomized Clinical Study to Evaluate the Efficacy, Safety and Genetic Polymorphism of Hypoca(Barnidipine)and Adalat OROS(Nifedipine) in Mild to Moderate Hypertensive Patients

Conditions
-----------------
Hypertension

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 20 90 years old patient mild to moderate hypertensive patients can finish this study can sign agreement Exclusion Criteria: severe hypertension Heart failure, Arrhythmia Liver or kidney failure pregnant women allergy to dihydropyridines attend other clinical trials in past 3 month

Ages Eligible for Study
-----------------
Minimum Age: 22 Years
Maximum Age: 87 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypertension, SNP, Nifedipine, Barnidipine
Substituted Frozen Embryo Transfer Cycles With GnRH-agonist Supplementation

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to compare two FET protocols by modifying the substituted FET cycle in order to maintain a higher ongoing positive pregnancy rate and thus reduce the early pregnancy loss. Hypothesis: adding GnRH-agonist to the substituted cycle in FET treatment reduces the early pregnancy loss.

Official Title
-----------------
Substituted Frozen Embryo Transfer Cycles With GnRH-agonist Supplementation

Conditions
-----------------
Pregnancy Loss, Frozen Embryo Transfer

Intervention / Treatment
-----------------
* Drug: Estradiol and progeterone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Endometrial thickness ≥ 7 mm after stimulation 18-45 years IVF/ICSI fertilisation BMI > 18,5 <30 kg/m2 cycle length 25-34 days Exclusion Criteria: endometrial thickness < 7 mm or no triple layer endometrium and/or functional follicles Uterine abnormality Chronic medical disease oocyte donation cycles

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Substituted FET cycle and GnRHa<br>Substituted FET GnRH-a 2 bolus two days before Estradiol 6 mg Progesterone (Crinone) 180 mg | Drug: Estradiol and progeterone<br>* Estradiol and progesterone<br>* Other names: Estradiol and progesterone;|
| Active Comparator: Substituted FET cycle<br>substituted FET cycle Estradiol Progesterone | Drug: Estradiol and progeterone<br>* Estradiol and progesterone<br>* Other names: Estradiol and progesterone;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pregnancy loss rate |  | Primary outcome is avaible after 12th week of gestational. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pregnancy rate |  | 14 days after embryo transfer. |